Analysts expect $21.8b 2012 Teva revenue
Teva will announce its 2012 business outlook at a live webcast next Wednesday.
The analysts full-year 2012 consensus is $5.67 earnings per share on $21.8 billion revenue. Their fourth quarter 2011 consensus is $1.57 earnings per share on $5.57 billion revenue, and the full-year consensus is $4.95 earnings per share on $18.3 billion revenue.
Factors that will strongly affect Teva's results for the fourth quarter of 2011 and first half of 2012 include a launch of a generic version of Pfizer Inc. (NYSE: PFE; LSE: PFZ) anti-cholesterol drug Lipitor.
Teva's share price has fallen 24% this year, although it has risen 6.5% in the past three months. The share price fell 1% in early trading on the TASE today to NIS 152.90, after rising 0.1% on Nasdaq yesterday to $40.90, giving a market cap of $36 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on December 14, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
- Tel Aviv market report
- Tel Aviv Stock Exchange
- Israeli stocks in NY
- Arbitrage gaps for dual-listed stocks
- Israeli stocks in Europe
- Israeli stocks on other markets
- Tel Aviv 25 options
- Mutual funds
- Current representative shekel rates
- Historical representative shekel rates
- Bank shekel rates
- Shekel/dollar options